31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Semaglutide patent battle heats up with new blow for Novo in India

6 February 2026 A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.

Careers

Wilson Sonsini senior counsel moves to a rival firm

6 February 2026 The New York-based partner will advise biotech, pharma, and technology clients on patent prosecution, IP strategy and venture-backed transactions.

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

More features

Nine-partner litigation team leaves Winston & Strawn

Firm adds seven-lawyer team in second major merger

Rooted in rights: Lessons from plant patent infringement and invalidity cases

Final call: Who are the world’s best in-house counsel?

How AI will be shaped by legal and regulatory developments in 2026

Bird & Bird targets Nordic life sciences growth with regulatory hire

Key EU and UK regulatory changes to watch for in 2026

Regeneron v Alvotech: The big impact

Copyright compliance in the life sciences industry

More on this story

Editor's picks

Editor's picks

More features